The Indian AI Research Organisation (IAIRO), a fast-rising institution at the centre of India's sovereign artificial intelligence ambitions...

Market veteran Ambareesh Baliga suggests pharmaceutical stocks offer a safe haven amidst currency volatility and cautious foreign investor ...

Happy Thursday! VCs are doubling down on India’s deeptech, with early-stage bets leading the charge. This and more in today’s ETtech Mornin...

India's pharmaceutical landscape is on the verge of transformation! The country’s drug regulatory body is gearing up for an overhaul with t...

UFO disclosure advocate David Wilcock died by suicide on April 20, 2026, following a mental health crisis response. His death occurred amid...

Sankaran Naren explains why markets are more attractive but unlikely to deliver outsized returns and shares his macro-driven approach with ...

Global private equity fund Warburg Pincus is nearing a deal to buy Koye Pharma. The Mumbai-based drugmaker focuses on women's health, respi...

Private equity firm Advent International has completed its majority acquisition of Indian contract development and manufacturing organisati...

Allam, who served as the CEO at the Public Investment Fund prior to joining Cadila Pharmaceuticals, will report to Group Chairman and Manag...

After a month gap in choosing the new CEO after Michel Vounatsos, Biogen has finally named Christopher Viehbacher as its new CEO.

Bharat Shah, executive director at ASK Group and a mentor to many on Dalal Street, said the financial services sector in the country has a ...

Singh was a pharma industry veteran with over 43 years of experience in the Indian pharmaceutical industry.

Among the changes proposed by the govt is the move to introduce a new price index for pharmaceutical products that will become the benchmar...

Sawhney joined Ranbaxy in 2008, as the head of the API (active pharmaceutical ingredient) business and global manufacturing and supply chai...

He has been a member of Ranbaxy's executive committee and has held positions on boards of various overseas subsidiaries of the pharma major.

In the past two years, Indian drug makers have come under severe scrutiny from the USFDA for flouting manufacturing practice norms.

Humer was the driving force behind Roche's acquisition of U.S. biotech company Genentech and has been the chairman for more than a decade.